(Q37353448)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Richard O. Day

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Garry G Graham

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sophie L Stocker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ian Portek

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Kevin D Pile

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Praveen L Indraratna

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Indira Datta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Kenneth M Williams

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

1 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Clinical Pharmacology

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

932-938

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

28 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

The pharmacokinetics of oxypurinol in people with gout

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Adherence with urate-lowering therapies for the treatment of gout

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Relation between adverse events associated with allopurinol and renal function in patients with gout

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Prediction of creatinine clearance from serum creatinine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Allopurinol hypersensitivity syndrome: a review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Quantification of lean bodyweight.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Allopurinol in treatment of gout.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3845316

Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?

2 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FBCP.12126

Renal clearance of oxipurinol, the chief metabolite of allopurinol

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FBCP.12126

British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout

21 January 2018

1 reference

12 December 2020

Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout

1 reference

12 December 2020

Allopurinol in the Treatment of Gout

1 reference

12 December 2020

Gout medication treatment patterns and adherence to standards of care from a managed care perspective

1 reference

12 December 2020

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol

1 reference

12 December 2020

Uric acid lowering therapy: prescribing patterns in a large cohort of older adults

1 reference

12 December 2020

Renal transport of urate during diuretic-induced hypouricemia

1 reference

12 December 2020

Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test

1 reference

12 December 2020

EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT

1 reference

12 December 2020

Furosemide increases plasma oxypurinol without lowering serum urate - a complex drug interaction: implications for clinical practice

1 reference

12 December 2020

Identifiers

DOI

10.1111/BCP.12126

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590252%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PubMed publication ID

23590252

1 reference